🔍
Genomic Drivers of Response to Immunotherapy
Case ID:
C15671
Report of Invention:
1/21/2019
Web Published:
10/9/2019
Unmet Need
Tumor mutational burden (TMB) is a measurement of mutations carried by tumor cells and is but one emerging biomarker for some types of cancer, including non-small cell lung cancer. Currently, there is a lack of standardization for tumor mutational burden calculation and reporting. Different tests may report different measurements, and since there is currently no one way of calculating TMB it is difficult to use as a biomarker. To achieve consistency and accurate reporting across tests, it is imperative to create some sort of standardization to arrive at clinically meaningful results, which will support informed decision-making for patients.
Technology Overview
Researchers at Johns Hopkins University have recently developed a new diagnostic algorithm which integrates several molecular markers to more accurately calculate response to immune checkpoint blockade therapies. Investigators developed a new method to estimate ‘corrected tumor mutation burden’ (cTMB) adjusted for tumor purity within specimen samples that more accurately predicts treatment outcome. Unlike current companion diagnostics for immune checkpoint therapies that measure one or two tumor indications, this new diagnostic algorithm can identify individuals that will respond or progress on immunotherapy using a model that incorporates corrected tumor mutation burden, smoking-related mutation signatures, receptor tyrosine kinase (RTK) activating mutations, and HLA genetic variation. This new approach is an improvement in personal genome diagnostics which aims to complement current cancer immune checkpoint blockade therapies.
Stage of Development
Clinical data available
Publications
Anagnostou
et al.
Dynamics of Tumor and Immune Responses during Immune Checkpoint
Blockade
in Non-Small Cell Lung Cancer.
Cancer Res.
2019
Mar 15;79(6):1214-1225.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER
PCT: Patent Cooperation Treaty
United States
17/598,690
9/27/2021
Pending
Direct Link:
https://jhu.technologypublisher.com/technology/36550
Inventors:
Category(s):
Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Computers, Electronics & Software > Algorithms,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum